CNS & neurological disorders drug targets · 2026
Tirofiban-Nimodipine Combination Therapy for Early Neurological Deterioration in Small Artery Occlusion Stroke: A Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tan Changhong, Yang Jiali, Yang Qian, Yang Hui, Liu Jun, Zhang Yin, Tian Junyuan, Huang Lijiang, Zeng Baozhen, Wu Xuefen, Feng Xiaopeng
Аннотация
INTRODUCTION: Early neurological deterioration (END) affects approximately 30% of patients with small artery occlusion (SAO) stroke. The combination of tirofiban and nimodipine may simultaneously address microthrombosis and vasospasm, two key mechanisms underlying SAOrelated END.
METHODS: In this retrospective cohort study, we analyzed data from consecutive SAO-END patients treated within two hours of END onset between January 2023 and December 2024. The combination group (n=50) received tirofiban plus nimodipine, while the control group (n=53) received tirofiban alone. The primary outcome was early neurological improvement (ENI), defined as a ≥ 2-point reduction in NIHSS score or ≥ 1-point improvement in motor function at 7 days or discharge. Secondary outcomes included a favorable functional outcome (mRS ≤2) at 90 days and safety events.
RESULTS: The combination group demonstrated significantly higher rates of ENI (76% vs. 47.2%; adjusted odds ratio [aOR] 3.96, 95% CI 1.32-11.90; p=0.014) and improved 90-day functional outcomes (84% vs. 58.5%; aOR 4.744, 95% CI 1.212-18.567; p=0.025). Higher admission NIHSS scores (aOR 0.759, 95% CI 0.612-0.941; p=0.012) and diabetes (aOR 0.201, 95% CI 0.048-0.840; p=0.028) were inversely associated with ENI. Older age (aOR 0.933, 95% CI 0.876-0.994; p=0.032) and higher admission NIHSS score (aOR 0.592, 95% CI 0.447-0.784; p=0.000) were negatively correlated with 90-day outcomes. Safety profiles were comparable between groups, with no instances of intracranial hemorrhage or hypotension. The addition of nimodipine did not significantly affect blood pressure.
DISCUSSION: Combining tirofiban and nimodipine may improve outcomes in SAO-related early neurological deterioration. If validated in future randomized trials, this combination could address a significant unmet need in a common stroke subtype with high risk of deterioration, potentially influencing clinical practice and guiding further research into multimodal neuroprotection strategies for cerebral small vessel disease.
CONCLUSION: Tirofiban-nimodipine combination therapy was found to be associated with enhanced early neurological recovery in SAO-END patients, warranting further investigation through larger multicenter randomized controlled trials.
METHODS: In this retrospective cohort study, we analyzed data from consecutive SAO-END patients treated within two hours of END onset between January 2023 and December 2024. The combination group (n=50) received tirofiban plus nimodipine, while the control group (n=53) received tirofiban alone. The primary outcome was early neurological improvement (ENI), defined as a ≥ 2-point reduction in NIHSS score or ≥ 1-point improvement in motor function at 7 days or discharge. Secondary outcomes included a favorable functional outcome (mRS ≤2) at 90 days and safety events.
RESULTS: The combination group demonstrated significantly higher rates of ENI (76% vs. 47.2%; adjusted odds ratio [aOR] 3.96, 95% CI 1.32-11.90; p=0.014) and improved 90-day functional outcomes (84% vs. 58.5%; aOR 4.744, 95% CI 1.212-18.567; p=0.025). Higher admission NIHSS scores (aOR 0.759, 95% CI 0.612-0.941; p=0.012) and diabetes (aOR 0.201, 95% CI 0.048-0.840; p=0.028) were inversely associated with ENI. Older age (aOR 0.933, 95% CI 0.876-0.994; p=0.032) and higher admission NIHSS score (aOR 0.592, 95% CI 0.447-0.784; p=0.000) were negatively correlated with 90-day outcomes. Safety profiles were comparable between groups, with no instances of intracranial hemorrhage or hypotension. The addition of nimodipine did not significantly affect blood pressure.
DISCUSSION: Combining tirofiban and nimodipine may improve outcomes in SAO-related early neurological deterioration. If validated in future randomized trials, this combination could address a significant unmet need in a common stroke subtype with high risk of deterioration, potentially influencing clinical practice and guiding further research into multimodal neuroprotection strategies for cerebral small vessel disease.
CONCLUSION: Tirofiban-nimodipine combination therapy was found to be associated with enhanced early neurological recovery in SAO-END patients, warranting further investigation through larger multicenter randomized controlled trials.